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Does ALS-FUS without FUS mutation
represent ALS-FET? Report of three cases
Abnormal cytoplasmic accumulation of fused in sar-
coma (FUS) protein is the pathological hallmark of
some cases of amyotrophic lateral sclerosis (ALS) with
transactive response DNA-binding protein of 43KDa
(TDP-43)-negative pathology that lack SOD1 muta-
tions. FUS is an RNA-binding protein located predomi-
nantly in the nucleus and is involved in regulation of
transcription, alternative splicing, RNA stability, micro-
RNA biogenesis, apoptosis and cell division. FUS,
Ewing’s sarcoma (EWS) and TATA-binding protein-
associated factor 15 (TAF15) proteins constitute the
FET (FUS/EWS/TAF15) family, highly conserved and
ubiquitously expressed RNA-binding proteins that shut-
tle between nucleus and cytoplasm assisted by the
nuclear import protein Transportin 1 (Trn1) [1].
Accumulation of FUS also occurs in other related
neurodegenerative conditions such as atypical fron-
totemporal lobar degeneration with ubiquitinated inclu-
sions (aFTLD), neuronal intermediate filament inclusion
disease (NIFID) and basophilic inclusion body disease
(BIBD), the three currently recognized forms of fron-
totemporal lobar degeneration with FUS pathology
(FTLD-FUS) [2].
Recent work suggests different pathological processes
underlie ALS-FUS and FTLD-FUS. First, most ALS-FUS
cases are caused by FUS mutations [3], while most
FTLD-FUS cases are not [2,4]. Neumann et al. described
that in ALS-FUS, the cytoplasmic inclusions consist
solely of FUS protein while in FTLD-FUS, the inclusions
include other FET family proteins such as TAF15 or
EWS [5]. In addition, they observed that Trn1, a pro-
tein involved in the nuclear transport, accumulates
specifically in FTLD-FUS inclusions but not in ALS-FUS.
These findings led the authors to suggest that ALS with
FUS mutations is more restricted to FUS dysfunction,
while in FTLD-FUS, there is a more global and complex
dysregulation of all FET proteins. They suggest chang-
ing the nomenclature and recommended using the
term FTLD-FET for FTLD-FUS but to preserve the term
ALS-FUS [5].
We describe three cases of ALS-FUS with TAF15 and
Trn1 accumulation in which FUS mutations were not
detected. Brain donors and/or next of kin had given
their written informed consent for the use of brain tis-
sue for research, and the research protocol has been
approved by the Ethics Committee of the Hospital Clinic
Barcelona.
Patient 1, a 63-year-old man, developed slowly pro-
gressive weakness in the distal muscles, dysarthria and
dysphagia. Neurological examination revealed symmet-
rical weakness and hyperreflexia, fulfilling the criteria
for ALS. Cognitive and behavioural symptoms were not
reported during follow-up. He died of respiratory failure
at 69 years. After brain donation, the unfixed brain
weight was 1390 g. A prominent atrophy of the
medullary pyramids, anterior nerve roots and spinal
cord was appreciated on gross examination, but with-
out brain atrophy. Histologically, prominent neuronal
loss of motor neurones of the anterior horn was
observed at all levels of the spinal cord and was also
present in the motor nuclei of the brain stem and the
primary motor cortex. Degeneration of the corticospinal
tracts was also observed. Several of the remaining
spinal and cortical motor neurones showed relatively
large cytoplasmic basophilic inclusions. These inclu-
sions were also observed in nonmotor pyramidal neu-
rones and were partly basophilic and partly fibrillar.
These inclusions were immunoreactive for FUS protein,
p62, TAF15 and Trn1 (Figure 1A1–A5), and partially
for ubiquitin, alpha-internexin and phosphorylated
neurofilaments. These findings were consistent with
ALS with FUS-positive basophilic and fibrillary inclu-
sions.
Patient 2, a 71-year-old woman, presented with pro-
gressive weakness of lower extremities, dysarthria and
dysphagia. Neurological examination revealed pyrami-
dal signs. No lower motor neurone signs were found
on examination, and she was diagnosed with primary
lateral sclerosis. During the disease course, she devel-
oped an akinetic–rigid syndrome without response to
levodopa. DAT-SPECT showed bilaterally reduced
putaminal tracer uptake. No cognitive symptoms were
reported. The patient died at the age of 83 years after
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a total disease duration of 12 years. After brain dona-
tion, the unfixed brain weight was 1035 g. Gross
examination showed moderate brain atrophy with pref-
erential involvement of the frontotemporal regions. Dif-
fuse nigral pallor was also observed. Histologically,
severe loss of motor neurones at all levels of the spinal
cord and brain stem nuclei was observed. In contrast,
no prominent neuronal loss of primary motor cortex
neurones and no unequivocal signs of corticospinal
tract degeneration were identified. In addition, there
was a depletion of pigmented neurones of the substan-
tia nigra and neuronal loss and gliosis of the subthala-
mic nucleus and internal pallidum. Residual motor
neurones of the spinal cord and hypoglossal nucleus
showed relatively large, faintly basophilic inclusions
that showed strong FUS immunoreactivity (Fig-
ure 1B1–B4) and were negative for ubiquitin, neurofil-
aments and TDP-43. Some FUS-positive glial inclusions
were also identified. Most of these inclusions showed
immunoreactivity for TAF15 and Trn1 antibodies (Fig-
ure 1B4). The final diagnosis was motor neurone
disease with preferential involvement of lower motor
neurones with pallidoluysian atrophy and nigral
degeneration with abundant neuronal and lesser glial
FUS-positive inclusions. Concomitantly, advanced Alz-
heimer’s disease neuropathological change (A3, B3, C3
score according to the NIAA/AA consensus criteria)
was found [6].
Patient 3, a 43-year-old man, presented with leg
weakness. On neurological examination, there was gen-
eralized amyotrophy, fasciculations and hyperreflexia.
He developed dysarthria and dysphagia during follow-
up and died of pneumonia at the age of 48 years. Cog-
nitive and behavioural symptoms were not reported.
The clinical diagnosis was ALS. He had no family his-
tory of ALS or dementia. After brain donation, the
unfixed brain weight was 1500 g. Gross examination
revealed mild brain atrophy with preferential involve-
ment of the precentral and postcentral gyri. Histologi-
cally, loss of motor neurones was evident in the
primary motor cortex, hypoglossal nuclei and also at
all levels of the spinal cord. Moreover, in the pre- and
postcentral regions as well as in the temporal cortex,
laminar spongiosis and gliosis were evident in superfi-
cial cortical layers. While with H&E staining, inclusions
were difficult to identify (Figure 1C1), immunohisto-
chemistry for FUS showed frequent neuronal cytoplas-
mic inclusions (Figure 1C2), short neurites and few
intranuclear inclusions. Inclusions were more abun-
dant in the precentral gyrus, in the brainstem nuclei
and in the spinal cord. They were also immunoreactive
for TAF15 and Trn1 (Figure 1C4–C5) and were nega-
tive for TDP-43. The final diagnosis was ALS-FUS. In
all three cases, granular neurones of the dentate gyrus
were devoid of inclusions (Figure 1A3, B3, C3 and
insets).
Genetic analysis of the FUS gene was performed in
the three donors. All 15 FUS exons including intron–
exon flanking regions, as well as the 30UTR region of
FUS gene, were amplified through PCR. Final PCR
products were purified and Sanger-sequenced using
BigDye terminator chemistry (Applied Biosystems).
Sequences were run on an Applied Biosystems 3130
Genetic Analyzer, and resulting electropherograms
were visually inspected using Sequencher (version 4.1,
Gene Codes Corp.). Genetic analysis did not disclose
any FUS mutation in any of these three patients. Since
several variants in the 30 untranslated region (30UTR)
of the FUS gene have been described with uncertain
pathogenicity (that is c.∗48G>A, c.∗59G>A,
c.∗108C>T and c.∗110G>A) [7,8], we also screened
the genomic region containing these variants. We only
Figure 1. Representative neuropathological findings in the three cases: (A1, B1, C1) HE-stained sections show different types of
intraneuronal inclusion bodies in the motor neurones of the frontal cortex, brainstem and spinal cord (arrows) varying in shape and
tinctorial properties (basophilic, pale, with a condensed centre or with fibrillar appearance). (A2, B2, C2) Inclusions are FUS-positive and
appear either compact, more fibrillar or skein-like (inset) (immunohistochemistry for FUS; slightly counterstained with haematoxylin).
(A3, B3, C3) There is no involvement of the dentate gyrus of the hippocampus, and granule cells are devoid of FUS/TAF15/Trn1 +
inclusion bodies (immunohistochemistry for FUS (A3, B3 and insets), TAF15 (C3 and insets) and Transportin 1 (Trn1)(insets)). (A4, B4,
C4) Intraneuronal inclusion bodies in motor cortex, brainstem and spinal cord neurones are also strongly immunoreactive for
Transportin 1 and TAF15 (immunohistochemistry for Transportin 1 (Trn1) and TAF15 shown in the left and right panel, respectively;
slightly counterstained with haematoxylin). A5: Double immunofluorescence for FUS (red, left panel), Trn1 (green, middle panel) and
merged image (yellow-orange, right panel) shows codistribution of both proteins in the same inclusion body in patient 1. C5: Double
immunofluorescence for TAF15 (red, left panel), Trn1 (green, middle panel) and merged image (yellow-orange, right panel) shows
codistribution of both proteins in the same inclusion body in patient 3. A1–A5 are from patient 1, B1–B4 are from patient 2, and C1–C5
are from patient 3. Scale bars: A1, B1, C1, A2, B2, C2, A4, B4, C4: 20 lm, A3, B3, C3: 50 lm.
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found one patient harbouring the c.*41G>A rare
heterozygous variant (rs80301724) [9]. Previous stud-
ies have reported this polymorphic variant to be
equally present in ALS cases and controls, thus show-
ing a lack of genetic association between this particular
nucleotide change and ALS [8,10].
Here, we describe the clinicopathological phenotype
of three ALS patients with abundant FUS-positive pro-
tein aggregates. The inclusion bodies were also
immunoreactive for TAF15 and Trn1, and no mutation
in the FUS gene was detected. Similar cases had been
reported in Japan by Matsuoka et al., Fujita et al. and
Takeuchi et al. (Table 1)[11–13]. Other possible genes
that could have mutations include TPN1 and TAF15,
among others, that were not tested in our cases.
These findings differ from the ALS-FUS cases previ-
ously reported by Neumann and behave immunohisto-
chemically similar to FTLD-FET cases. Whether these
cases might be specific to certain populations is unre-
solved. Based on our results, we confirm the concept
that the presence of FET and Trn1 proteins within the
inclusions is strong indicator of a lack of pathogenic
mutations within FUS. However, this immunohisto-
chemical profile does not differentiate between an ALS
and FTLD phenotype. If we hypothesize that FTLD-FUS
with FUS mutations will not show Trn1 or any other
FET family protein than FUS, a change of the nomen-
clature in the ALS-FUS and FTLD-FUS with no muta-
tions of FUS should be considered, and the use of the
terms ALS-FET and FTLD-FET might be more appropri-
ate.
ALS-FUS mutation cases seem to have different mor-
phological phenotypes depending on the age of onset or
disease duration; neuronal basophilic inclusions being
more frequently detected in early juvenile forms, while
fibrillary or tangle-like inclusions and glial inclusions
tend to appear in late-onset cases [3]. Similar findings
have been described in some sporadic FTLD-FUS cases
[4,14]. Interestingly, ALS-FUS cases without FUS
mutations seem to have an older age of onset and a
less aggressive progression than cases with mutations
[3].
While some reports have detected FUS mutations in
‘juvenile ALS with basophilic inclusions’ [15], others
have not found mutations in the adult-onset group
[11,12]. It might be therefore that a subgroup of
‘adult-onset ALS with basophilic inclusions’ represents
the ALS counterpart of basophilic inclusion body dis-
ease and may therefore be considered an ALS-FET sub-
type without FUS mutations.
Our study expands the clinicopathological spectrum
of nongenetic ALS-FUS cases and reinforces the idea
that not all ALS-FUS cases are secondary to FUS muta-
tions. It also corroborates the usefulness of TAF-15 and
Trn1 immunohistochemistry for the neuropathological
diagnosis of nongenetic FTLD-FET and ALS-FET
patients. Whether these cases represent a different
pathogenetic subgroup among ALS-FUS is unclear and
Table 1. Demographic and clinical features of ALS-FUS cases in the literature
Present study
Fujita et al. [10] Matsuoka et al. [11] Takeuchi et al. [12]Patient 1 Patient 2 Patient 3
Gender Male Female Male Female Female Female
Family history No No No No No No
FUS mutation No No No No No No
Age at onset (y) 63 71 43 73 75 73
Age at death (y) 69 83 48 75 79 75
Motor neurone Yes Yes Yes Yes Yes Yes
Onset Spinal Spinal Spinal Spinal Spinal Spinal
Dementia No No No No No No
Parkinsonism No Yes No No No No
Neuropathology ALS-FUS ALS-FUS ALS-FUS ALS-FUS ALS-FUS ALS-FUS
FUS IHC + + + + + +
TAF15 IHC + + + NE NE +
TRN1 IHC + + + NE NE +
ALS, amyotrophic lateral sclerosis; FUS, fused in sarcoma; NE, not evaluated; y, years; IHC, immunohistochemistry.
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requires further detailed clinical, neuropathological and
molecular studies.
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